Pharmacokinetic profiles of controlled-release hydrogel polymer vaginal inserts containing misoprostol

Journal of Clinical Pharmacology

Volumn 48, Issue 1, 2008, Pages 26-34

  Powers, Barbara L ^a   Wing, Deborah A ^b   Carr, Denis ^c   Ewert, Karine ^c   Di Spirito, Mike ^d  

^a Cytokine PharmaSciences Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Controlled Therapeutics ^*  (United Kingdom)

^d MDS Inc   (Canada)

Author keywords

Cervical ripening; Controlled release; Induction of labor; Misoprostol; Pharmacokinetics; Vaginal insert

Indexed keywords

15 DEOXY 16 HYDROXY 16 METHYLPROSTAGLANDIN E1; DRUG METABOLITE; MISOPROSTOL; POLYMER; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HYDROGEL; NORMAL HUMAN;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLIC; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FEMALE; HALF-LIFE; HUMANS; HYDROGELS; MISOPROSTOL; OXYTOCICS; POLYMERS; TABLETS; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 37349011292     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007309707     Document Type: Article

References (9)

1. Hofmeyer GJ, Gulmezoglu AM Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2003 ;(1). CD000941.
2. Sanchez-Ramos L., Kaunitz AM Misoprostol for cervical ripening and labour induction: a systematic review of the literature. Clin Obstet Gynaecol. 2000 ; 43: 475-488.
3. Ramsey P., Meyer L., Walkes B., et al. Cardiotocographic abnormalities associated with dinoprostone and misoprostol cervical ripening. Obstet Gynecol. 2005 ; 105: 85-90.
4. Monk JP, Clissod SP Misoprostol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease. Drugs. 1987 ; 33: 1-30.
5. Karim A., Rozek LF, Smith ME, Kowalski KG Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. J Clin Pharmacol. 1989 ; 29: 439-443.
6. Zieman M., Fong SK, Benowitz NL, Bankster D., Darney D. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997 ; 90: 88-92.
7. Tang OS, Schweer H., Seyberth HW, Lee SWH, Ho PK Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod. 2002 ; 17: 332-336.
8. Schaff EA, DiCenzo R., Fielding SL Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception. 2005 ; 71: 22-25.
9. Alexander NJ, Baker E., Kaptein E., Karck U., Miller L., Zampaglione E. Why consider vaginal drug administration? Fertility Sterility. 2004 ; 82: 1-12.